Flinton Capital Management LLC increased its holdings in Biogen Inc (NASDAQ:BIIB) by 59.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,824 shares of the biotechnology company’s stock after purchasing an additional 8,160 shares during the period. Flinton Capital Management LLC’s holdings in Biogen were worth $6,953,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in the company. Captrust Financial Advisors purchased a new stake in Biogen during the 4th quarter valued at $113,000. Prentiss Smith & Co. Inc. purchased a new stake in Biogen during the 4th quarter valued at $123,000. Harel Insurance Investments & Financial Services Ltd. boosted its position in Biogen by 77.0% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 174 shares during the period. Horan Capital Advisors LLC. purchased a new stake in Biogen during the 3rd quarter valued at $128,000. Finally, Massey Quick Simon & CO. LLC boosted its position in Biogen by 84.8% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 195 shares during the period. 88.96% of the stock is owned by institutional investors.
Biogen Inc (NASDAQ BIIB) opened at $283.24 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 2.07. The stock has a market cap of $59,216.40, a PE ratio of 23.76, a P/E/G ratio of 1.54 and a beta of 0.90. Biogen Inc has a 12 month low of $244.28 and a 12 month high of $370.57.
Several brokerages have weighed in on BIIB. Deutsche Bank reissued a “buy” rating and set a $373.00 price target on shares of Biogen in a research report on Friday, January 26th. Oppenheimer increased their price target on shares of Biogen from $380.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, January 26th. Jefferies Group reissued a “hold” rating on shares of Biogen in a research report on Friday, January 26th. BMO Capital Markets reissued a “buy” rating on shares of Biogen in a research report on Thursday, January 25th. Finally, Cowen reissued a “buy” rating and set a $408.00 price target on shares of Biogen in a research report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and twenty-two have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $370.07.
In related news, EVP Alfred Sandrock sold 1,294 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $298.85, for a total value of $386,711.90. Following the completion of the transaction, the executive vice president now directly owns 7,296 shares in the company, valued at approximately $2,180,409.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michel Vounatsos purchased 780 shares of the firm’s stock in a transaction that occurred on Friday, December 29th. The stock was acquired at an average price of $320.55 per share, with a total value of $250,029.00. Following the completion of the purchase, the chief executive officer now owns 4,879 shares in the company, valued at $1,563,963.45. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 8,128 shares of company stock valued at $2,601,512. 0.25% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/03/14/flinton-capital-management-llc-increases-stake-in-biogen-inc-biib.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.